Biomedical sciences

Rose Hill Partners with University of Guelph for Groundbreaking Study to Advance Research for the Potential Benefits of Psilocybin Mushrooms to Address Autism in the Adolescent Brain

Retrieved on: 
Thursday, March 21, 2024
Psilocybin, University of Guelph, Research, Certification, Brain, Learning, University, Memory, Associate, Partnership, Patient, Knowledge, Fungus, Agriculture, Anxiety, Adolescence, Autism spectrum, Biomedical sciences, Spectrum, ASD, Biomass, Pharmaceutical industry

This collaboration marks a significant milestone for both entities as they embark on a pioneering exploration of the potential benefits of psilocybin to address autism in the adolescent brain, the first-of-its-kind partnership in this space.

Key Points: 
  • This collaboration marks a significant milestone for both entities as they embark on a pioneering exploration of the potential benefits of psilocybin to address autism in the adolescent brain, the first-of-its-kind partnership in this space.
  • The collaborative preclinical research will focus on exploring and standardizing the chemical diversity of Rose Hill’s psilocybin mushrooms, legally imported from Jamaica to Canada for the work.
  • Additionally, utilizing a rodent model, the study will investigate their potential application in Autism Spectrum Disorders (ASD).
  • Psilocybin mushrooms, known for their psychoactive properties, have long captivated the scientific community's interest due to their potential therapeutic applications and unique biochemical composition.

PCOM, The Wistar Institute Announce Cancer Biology Graduate Program

Retrieved on: 
Wednesday, March 20, 2024
Wistar Institute, Drug discovery, Patient, PCOM, Research, News, Cancer, Doctor of Philosophy, Faculty, Student, Drug development, Biomedical sciences, School

Program aimed at advancing research and cultivating the next generation of leaders in the fight against cancer.

Key Points: 
  • Program aimed at advancing research and cultivating the next generation of leaders in the fight against cancer.
  • , Wistar President and CEO, director of its Ellen and Ronald Caplan Cancer Center and the Robert and Penny Fox Distinguished Professor.
  • The Cancer Biology Graduate Program—jointly administered by Wistar and PCOM—will train individuals for a successful academic or industrial career in cancer biology and drug development.
  • At the conclusion of their studies, successful candidates will be granted a Ph.D. in cancer biology from PCOM.

Carina Biotech to Present Three Poster Presentations at AACR Annual Meeting 2024

Retrieved on: 
Monday, March 18, 2024
Ovarian cancer, Brain, Immunotherapy, Colorectal cancer, Patient, Lead, Research, Doctor of Philosophy, University of Adelaide, University, GMP, AACR, Biomedical sciences, Stomach, Liver, Pharmaceutical industry

ADELAIDE, Australia, March 18, 2024 (GLOBE NEWSWIRE) -- Carina Biotech Limited (Carina), a clinical stage cell therapy immuno-oncology company, today announced three poster presentations from studies of its LGR5-targeting CAR-T program in colorectal cancer and ovarian cancer at the American Association for Cancer Research (AACR) Annual Meeting 2024 that will take place in San Diego, California, on April 5-10.

Key Points: 
  • ADELAIDE, Australia, March 18, 2024 (GLOBE NEWSWIRE) -- Carina Biotech Limited (Carina), a clinical stage cell therapy immuno-oncology company, today announced three poster presentations from studies of its LGR5-targeting CAR-T program in colorectal cancer and ovarian cancer at the American Association for Cancer Research (AACR) Annual Meeting 2024 that will take place in San Diego, California, on April 5-10.
  • “We are looking forward to sharing data related to our LRG-5 targeted CAR-T program in three poster presentations at the upcoming AACR annual meeting.
  • One of the posters will highlight the GMP manufacturing and testing findings for our lead LGR5-targeted CAR-T cell therapy candidate CNA3103, that is currently being evaluated in a Phase 1/2 clinical trial for the treatment of adult patients with metastatic colorectal cancer,” stated Deborah Rathjen, PhD, Carina’s Chief Executive Officer.
  • “Our research team will also be presenting preclinical data that demonstrate the potential to develop our LGR5-targeting CAR-T cells as a novel immunotherapy for ovarian cancer and that expand the preclinical body of evidence across a diverse range of cancer families, including ovarian, brain, liver, and stomach, where LGR5-targeting CAR-T cells may be harnessed.”
    Lead Author: Jade Foeng, PhD, Chemokine Biology Laboratory, Department of Molecular and Biomedical Science, The University of Adelaide, South Australia

Zephyr AI Raises $111 Million in Series A Financing

Retrieved on: 
Wednesday, March 13, 2024
Technology, Clinical Trials, Professional Services, Cardiology, Software, General Health, Health, Data Management, Oncology, Artificial Intelligence, Algorithm, ARU, Gene expression, Entrepreneurship, Eli Lilly and Company, Patient, LLP, Nature, Revolution LLC, Cooley LLP, Medicine, Abstract, AACR, Drug development, Ecosystem, Biomedical sciences, Interim, Machine learning, Collection, Artificial intelligence, Pharmaceutical industry

Zephyr AI, Inc. (“Zephyr AI”), a healthcare technology company committed to developing fast and explainable Artificial Intelligence (AI) solutions to democratize precision medicine, today announced it has successfully closed a $111 million Series A funding round with participation from Revolution Growth, Eli Lilly & Company, Jeff Skoll, and EPIQ Capital Group, among others.

Key Points: 
  • Zephyr AI, Inc. (“Zephyr AI”), a healthcare technology company committed to developing fast and explainable Artificial Intelligence (AI) solutions to democratize precision medicine, today announced it has successfully closed a $111 million Series A funding round with participation from Revolution Growth, Eli Lilly & Company, Jeff Skoll, and EPIQ Capital Group, among others.
  • We must do better,” said Grant Verstandig, Zephyr AI’s Co-Founder and Executive Chairman.
  • “At Zephyr AI, we are harnessing the power of AI to extract novel insights to better define patient stratification and response predictions as well as improve federation of real-world data.
  • Cooley LLP served as legal counsel for Zephyr AI.

Open Call: Vilcek Foundation to Award $150,000 in Prizes to Immigrant Scientists in 2025

Retrieved on: 
Monday, March 25, 2024
IRS, Culture, Organization, Rheumatoid arthritis, Gene editing, Foundation (nonprofit), Humanities, Biomedical Research, Vilcek Foundation, Research, History, Messenger, Jan Vilček, Nobel Prize, Biomedical sciences, CRISPR, Creative, Therapy, Family, Parent, Medicine, Pharmaceutical industry

NEW YORK, March 25, 2024 /PRNewswire/ -- The Vilcek Foundation has announced an open call for applications for the 2025 Vilcek Prizes for Creative Promise in Science. Three prizes of $50,000 each will be awarded to young immigrant scientists in the United States whose early career work represents a significant contribution to their field. Applications will be accepted through June 10, 2024, at 5:00pm ET.

Key Points: 
  • The Vilcek Foundation will accept applications for the 2025 Vilcek Prizes for Creative Promise in Biomedical Science through June 10, 2024.
  • NEW YORK, March 25, 2024 /PRNewswire/ -- The Vilcek Foundation has announced an open call for applications for the 2025 Vilcek Prizes for Creative Promise in Science .
  • The Vilcek Prizes for Creative Promise are awarded to immigrant professionals living and working in the United States.
  • The Vilcek Prizes for Creative Promise are a part of the Vilcek Foundation Prizes program.

Vilcek Foundation announces expansion of Prizes Program: Open call for immigrant artists and curators

Retrieved on: 
Monday, March 25, 2024
IRS, Culture, Organization, Foundation (nonprofit), Humanities, Biomedical Research, Vilcek Foundation, History, Photography, Prize, Jan Vilček, Sculpture, Biomedical sciences, Drawing, Ceramic, Creative, Family, Parent, Creative industries

NEW YORK, March 25, 2024 /PRNewswire/ -- The Vilcek Foundation in 2025 will double the amount of prizes they award in the arts and humanities as part of the philanthropic organization's annual prize program. Applications for the 2025 Vilcek Prizes for Creative Promise in Visual Arts and in Curatorial Work are now open; applications will be accepted through June 10, 2024, at 5:00pm ET.

Key Points: 
  • The Vilcek Foundation will award $300,000 in prizes to immigrant artists and curators in 2025 with the Vilcek Prizes for Creative Promise in Visual Arts and the Vilcek Prizes for Creative Promise in Curatorial Work.
  • Since 2006, the foundation has awarded the Vilcek Foundation Prizes in Biomedical Science and in a rotating category in the arts and humanities.
  • The Vilcek Foundation Prizes are awarded to immigrant professionals living and working in the United States.
  • The Vilcek Foundation Prizes are composed of the Vilcek Prizes and the Vilcek Prizes for Creative Promise.

Four Rochester Internists Open New MDVIP-Affiliated Primary Care Practices

Retrieved on: 
Monday, March 25, 2024
Strong Memorial Hospital, Health, Internal medicine, Physician, State university system, Patient, Molina Healthcare, University, Dentistry, Buffalo, Suite, American College, Pharmacy, Rochester Regional Health, Biomedical sciences, Medicare, MDVIP, University School, Rochester General Hospital

ROCHESTER, N.Y. and BOCA RATON, Fla., March 25, 2024 /PRNewswire/ -- MDVIP, the market leader in personalized healthcare with a network of over 1,100 physicians nationwide, today announced that it has partnered with four board-certified internists in Greater Rochester, New York. Dr. James J. Iacobucci, Dr. Paul Burns, Dr. Edith Dale and Dr. Charis A. Lee have opened MDVIP-affiliated practices and are currently accepting patients who seek more time and a closer relationship with their primary care doctor.

Key Points: 
  • Dr. James J. Iacobucci , Dr. Paul Burns , Dr. Edith Dale and Dr. Charis A. Lee have opened MDVIP-affiliated practices and are currently accepting patients who seek more time and a closer relationship with their primary care doctor.
  • Dr. Burns is a Diplomate of the American Board of Internal Medicine and is affiliated with Rochester General Hospital.
  • She is affiliated with Rochester Regional Health and the University of Rochester Medical Center.
  • Eleven peer-reviewed, published studies show that patients in MDVIP-affiliated practices have better health outcomes compared to those in traditional primary care practices, including:
    79% fewer hospitalizations for Medicare patients, equating to $600 million savings in one year

The Brain Aneurysm Foundation and Families of Individuals Impacted by the Disease Join Forces to Advocate for Increased Research Funding and Education

Retrieved on: 
Tuesday, March 19, 2024
Research, Organization, Myenteric plexus, Prevalence, Aneurysm, Disease, Intracranial aneurysm, Caregiver, Education, DSM-IV codes, Biomarker, Policy, Patient, University, Death, Risk, Rupture, Tutino, Survivor, Subarachnoid hemorrhage, NINDS, Biomedical sciences, Murder of Ellie Gould, Bangladesh Technical Education Board, Family, Physician, Health, Pharmaceutical industry

HANOVER, Mass., March 19, 2024 /PRNewswire/ -- The Brain Aneurysm Foundation (BAF), the leading advocacy organization supporting education, research, and policy to transform the treatment of brain aneurysms, today joined with caregivers, survivors, researchers, and physicians from across the U.S. to advocate for greater funding and to increase awareness of brain aneurysms and the long-term impact they can have on individuals and their families.

Key Points: 
  • Worldwide, there are close to 500,000 deaths each year from brain aneurysms, half of which occur in people under the age of 50.
  • The family's extensive work to honor Katelyn, who died just months before her planned wedding, has led to their involvement in supporting increased funding for critical research.
  • 902 and S. 895), which would provide dedicated research for aneurysm prevention and improve the long-term outcomes for aneurysm survivors.
  • "Brain scans can be cost prohibitive and are often not recommended by a physician unless there is a family history of the disease.

Branded Legacy, Inc. Significantly Expands Asset Portfolio and Production Capacity Through Successful Acquisition of Sycamore BioPharma, Inc.

Retrieved on: 
Tuesday, March 12, 2024
Sycamore, Editor-in-chief, Growth, PHD, Biotechnology, Drug discovery, Patient, Research, Environmental technology, Acquisition, Cancer, Mentorship, DSM-IV codes, University, GMP, Clinical trial, Infection, Medical school, Adjunct, PharmaMar, Biomedical sciences, Family, Marketing, FDA, Biochimica et Biophysica Acta, Pharmaceutical industry

MELBOURNE, Fla., March 12, 2024 /PRNewswire/ -- Branded Legacy (OTC.PK: BLEG), Inc., a trailblazing BioTech holdings company, proudly announces the strategic acquisition of Sycamore BioPharma, Inc, a distinguished developer of plant-based pharmaceuticals. This strategic milestone not only fortifies Branded Legacy's standing as a prominent player in the biotech sector but also secures assets exceeding $2 million, along with key personnel crucial for advancing clinical trials following this successful union.

Key Points: 
  • The acquisition brings forth over $500,000 in high-quality, ready-to-sell inventory and aligns seamlessly with Branded Legacy's dedication to quality, authenticity, and a commitment to natural ingredients.
  • David Oswald, CEO at Branded Legacy, Inc., expresses enthusiasm about the acquisition, stating, "Branded Legacy is thrilled to embrace Sycamore BioPharma into our family of companies.
  • Tyler Stone, President of Sycamore Biopharma, Inc., is also enthusiastic about the acquisition stating, "Branded Legacy brings significant strengths in areas where Sycamore BioPharma was seeing significant challenges.
  • The collaboration between Branded Legacy and Sycamore BioPharma is poised to unlock synergies across various business facets.

Accumulus Synergy Adds Two World-Class Executives to Its Leadership Team

Retrieved on: 
Thursday, March 7, 2024
Human services, Marine Corps Expeditionary Medal, Training and development, Central Arkansas, Computer science, HHS, Human resources, University, Business administration, Biomedical sciences, CISO, Capella University, Automation, Texas A&M University, HITRUST, Veteran, Management

BURLINGAME, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Accumulus Synergy, Inc. (“Accumulus”) today announced the appointment of Chanille Juneau, Chief Product Officer, and Dr. Kevin Charest, Chief Information Security Officer.

Key Points: 
  • BURLINGAME, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Accumulus Synergy, Inc. (“Accumulus”) today announced the appointment of Chanille Juneau, Chief Product Officer, and Dr. Kevin Charest, Chief Information Security Officer.
  • “I am thrilled to add Chanille and Kevin to our team,” said Francisco Nogueira, Accumulus CEO.
  • Dr. Kevin Charest joins Accumulus Synergy from HITRUST, where he jointly served as Chief Information Security Officer and Chief Technology Officer.
  • At Accumulus Synergy, Dr. Charest is responsible for all aspects of the information security program and enterprise technology initiatives.